Glenmark Pharmaceuticals launches Clobetasol from its niche dermatology pipeline

Glenmark Pharmaceuticals Inc (GPI), the US subsidiary of Mumbai-based integrated specialty generic pharmaceuticals maker Glenmark Pharmaceuticals, has announced having launched the marketing and distribution of five clobetasol propionate dermatology products in the US market.

The company has acquired the US marketing rights for a line of clobetasol propionate products including cream, E cream, ointment gel and topical solutions through a US-based pharmaceutical development company.

This dermatology portfolio marks Glenmark's entry into the US semisolid product market.

Glenmark plans to launch an additional 11 dermatological products in the next 12 months.

Clobetasol propionate is used to treat diseases such as eczema and psoriasis and used on the scalp and body and counter autoimmune conditions such as hair loss due to autoimmune diseases (alopecia areata) and auto immune skin nodules (lichen planus).

Acording to the IMS Health report, the total sales for the five clobetasol propionate products in the 12 month period ending December 2007 were over $28 million.

Based on these recent launches, Glenmark's US subsidiary now has a portfolio of 28 generic products for the US market.

The company currently has over 35 ANDAs undergoing US FDA approval process / launch.